Australia Hormone Replacement Therapy Market – Treatment Trends & Forecast 2026–2034

Australia Hormone Replacement Therapy Market Size and Forecast 2026-2034

Australia Hormone Replacement Therapy Market is expected to reach US$ 427.28 Million by 2034 from US$ 245.93 Million in 2025, with a CAGR of 6.33% from 2026 to 2034. Australia’s hormone replacement therapy (HRT) market is expanding due to rising menopause awareness, increasing demand for symptom management, government initiatives supporting women’s health, wider reimbursement of menopause medicines, and growing adoption of personalized hormone therapies among aging female populations.

Australia Hormone Replacement Therapy Industry Overview

Hormone Replacement Therapy (HRT), also known as Menopausal Hormone Therapy (MHT), is widely used in Australia to manage menopause-related symptoms such as hot flushes, night sweats, mood changes, vaginal dryness, and osteoporosis risk. The market includes estrogen-only therapies, combined estrogen-progesterone therapies, transdermal patches, gels, tablets, and vaginal formulations. Growing awareness regarding women’s health, improved diagnosis rates, and supportive government policies have strengthened market demand. Australia’s aging female population and increasing healthcare expenditure further support market growth. In addition, pharmaceutical companies continue to expand their menopause-care portfolios, improving treatment accessibility and patient outcomes.

The Australian HRT market is witnessing steady growth owing to increased awareness of menopause management and broader access to treatment options. Government-backed initiatives, including PBS funding for selected menopause therapies, are making treatments more affordable and accessible. Healthcare professionals are increasingly recognizing the benefits of evidence-based hormone therapy for symptom relief and quality-of-life improvement. Furthermore, Australia’s growing population of women aged above 45 years creates a large patient pool requiring menopause care. Pharmaceutical companies are also introducing newer formulations and expanding product availability, supporting market expansion. These factors collectively contribute to stronger adoption of HRT products across Australia.

Recent Developments in Australia Hormone Replacement Therapy Market

• In July 2025, a dedicated virtual menopause hub was introduced in South-West Sydney to provide both telehealth and face-to-face support for women experiencing perimenopause and menopause. The service is designed to enhance access to specialized menopause care and is expected to assist approximately 200 women each month across Western Sydney, the Blue Mountains, and the Riverina regions.

Growth Drivers for the Australia Hormone Replacement Therapy Market

Rising Menopause Awareness and Improved Diagnosis Rates

Increasing awareness of menopause and perimenopause is a major factor driving the growth of the Australia Hormone Replacement Therapy (HRT) market. Public discussions, educational campaigns, and growing media attention have encouraged more women to seek medical support for symptoms such as hot flushes, sleep disturbances, mood changes, and vaginal dryness. Healthcare professionals are also becoming more proactive in identifying menopause-related concerns and discussing treatment options, leading to higher diagnosis rates and increased HRT adoption. Furthermore, ongoing efforts to improve menopause education among clinicians are helping reduce treatment gaps and supporting evidence-based care. As awareness continues to rise, more women are expected to access hormone therapies, contributing to sustained market expansion across Australia.

In February 2025, the Australasian Menopause Society welcomed the Australian Government’s decision to fund menopausal hormone therapy medicines including Estrogel®, Prometrium®, and Estrogel Pro® through the Pharmaceutical Benefits Scheme (PBS). The initiative is expected to improve affordability and expand access to HRT for thousands of Australian women, thereby supporting market growth.

Expanding Availability of Advanced Hormone Therapy Products

The introduction of innovative hormone therapy products is strengthening the Australian HRT market by providing women with a wider range of treatment options. Demand is increasing for convenient and patient-friendly formulations that offer flexibility, ease of use, and personalized symptom management. Transdermal therapies, in particular, are gaining popularity because they provide an alternative to traditional oral treatments and can improve patient adherence. Pharmaceutical companies are actively expanding their menopause-care portfolios to address unmet needs and ensure greater treatment accessibility. The availability of diverse hormone delivery systems is helping healthcare providers tailor therapies according to individual patient requirements, thereby increasing overall treatment uptake and supporting long-term market growth.

In May 2026, Acrux Limited announced the licensing and planned Australian commercialization of Lenzetto®, a transdermal estradiol spray developed by Gedeon Richter. The product expands available menopausal hormone therapy options in Australia and is expected to help address supply shortages while providing women with an alternative hormone delivery method.

Strengthening Pharmaceutical Investments and Portfolio Expansion

Strategic investments and portfolio expansion by pharmaceutical companies are playing an important role in the development of Australia’s HRT market. Manufacturers are increasingly focusing on menopause care due to rising demand from the growing population of women entering perimenopause and menopause. Acquisitions, licensing agreements, and regional expansion strategies are helping improve the availability of established hormone therapies across Australia. These activities enhance supply reliability, strengthen distribution networks, and provide healthcare professionals with broader treatment choices. In addition, increased commercial interest in women’s health is expected to encourage future product innovation and market competition, ultimately benefiting patients through improved access and treatment outcomes.

In December 2024, ADVANZ PHARMA acquired the rights to Progynova® and Cyclo-Progynova® from Bayer in selected Asia-Pacific markets. The acquisition strengthened the company’s women’s health portfolio and supports continued access to established hormone replacement therapies across the region, including Australia, thereby contributing to market growth.

Challenges in the Australia Hormone Replacement Therapy Market

Supply Chain Disruptions and Product Shortages

One of the major challenges facing the Australian HRT market is the ongoing shortage of hormone therapy patches. Supply constraints resulting from manufacturing issues and sudden demand increases have affected the availability of several commonly prescribed products. These shortages can disrupt treatment continuity, forcing patients to switch therapies or experience delays in symptom management. Such disruptions may reduce patient confidence and create additional workload for healthcare professionals managing alternative treatment plans. Although authorities have allowed temporary imports of overseas alternatives, long-term supply stability remains a concern. Pharmaceutical companies and regulators must improve inventory planning and manufacturing resilience to ensure uninterrupted access to hormone replacement therapies across Australia.

Limited Clinical Awareness and Treatment Variability

Despite increasing awareness, significant variability remains in menopause diagnosis and treatment practices across Australia. Many healthcare professionals have historically received limited menopause-specific training, resulting in inconsistent prescribing patterns and delayed treatment initiation. Patients often encounter differing opinions regarding the benefits and risks of hormone therapy, which can create uncertainty and reduce adoption rates. Additionally, lingering concerns stemming from older studies continue to influence perceptions among both clinicians and patients. The lack of standardized national guidelines has contributed to inconsistent care pathways. While Australia is currently developing national clinical guidelines for perimenopause and menopause, education gaps remain a challenge that could temporarily limit market growth and treatment uptake.

New South Wales Hormone Replacement Therapy Market

New South Wales represents the largest hormone replacement therapy (HRT) market in Australia due to its large population base, advanced healthcare infrastructure, and strong concentration of specialist women's health clinics. Sydney serves as a major hub for menopause care, providing broad access to gynecologists, endocrinologists, and menopause specialists. Increasing awareness of menopause management and rising demand for symptom relief therapies continue to support market expansion. The state's extensive healthcare network also facilitates early diagnosis and treatment adoption among women entering perimenopause and menopause.

According to the Australian Bureau of Statistics (ABS), New South Wales had an estimated resident population of 8.60 million people as of June 2024, the highest among all Australian states. The large population creates a substantial target pool for menopause-related healthcare services and HRT products.

Victoria Hormone Replacement Therapy Market

Victoria is a key contributor to Australia's HRT market, supported by strong healthcare accessibility, high health literacy, and growing awareness of menopause treatment options. Melbourne hosts numerous women's health centers and research institutions that promote evidence-based menopause management. Demand for hormone therapies is increasing as more women seek treatment for vasomotor symptoms, sleep disturbances, and osteoporosis prevention. Government health initiatives and specialist services continue to improve patient access to menopause care across the state.

According to the Australian Bureau of Statistics, Victoria recorded approximately 7.05 million residents in June 2024, making it the second-most populous state in Australia. This large female population entering menopause age groups supports significant demand for HRT therapies.

Queensland Hormone Replacement Therapy Market

Queensland is emerging as one of the fastest-growing HRT markets in Australia due to strong population growth and a rising number of women aged 45 years and older. The state's healthcare providers are increasingly focusing on menopause management services, while telehealth expansion has improved access to specialist consultations in regional areas. Demand for HRT products is particularly strong among retirees and aging populations residing in coastal regions. Increasing awareness campaigns and healthcare investments are expected to further accelerate market growth.

According to the Australian Institute of Health and Welfare (AIHW), Queensland had approximately 1.03 million females aged 45 years and above in recent population estimates, representing a major target demographic for menopause and hormone replacement therapies.

Western Australia Hormone Replacement Therapy Market

Western Australia’s HRT market is expanding due to growing awareness of menopause care, increasing healthcare expenditure, and improved access to women's health services. Perth serves as the state's primary healthcare center, supporting the adoption of advanced menopause treatments and specialist consultations. The market also benefits from increasing use of telemedicine, which improves access to care for women living in remote and regional communities. Rising demand for symptom management and bone health preservation therapies is expected to sustain future market growth.

According to the Australian Bureau of Statistics, Western Australia recorded annual population growth of 2.8% in 2024, one of the fastest growth rates among Australian states and territories. Rapid population growth is expanding the potential patient base for menopause-related healthcare services and HRT products.

Australia Estrogen Hormone Replacement Therapy Market

The Australia Estrogen Hormone Replacement Therapy (HRT) market accounts for a significant share of the overall menopause treatment industry, primarily due to the widespread use of estrogen-based therapies for managing vasomotor symptoms, vaginal atrophy, and osteoporosis prevention. Estrogen therapies are available in multiple formulations, including tablets, gels, sprays, patches, and vaginal products, allowing healthcare providers to personalize treatment according to patient needs. Growing awareness regarding menopause management, increasing diagnosis rates, and improved affordability through government reimbursement initiatives are supporting market growth. Additionally, the introduction of innovative estrogen delivery systems and expanding product availability are encouraging adoption. As Australia's aging female population continues to increase, demand for estrogen-based therapies is expected to remain strong throughout the forecast period.

Australia Menopause Hormone Replacement Therapy Market

The Australia Menopause Hormone Replacement Therapy market is experiencing steady growth due to increasing awareness of menopause-related health issues and greater acceptance of hormone-based treatments. Women are increasingly seeking medical support for symptoms such as hot flushes, sleep disturbances, mood fluctuations, and reduced bone density. Government initiatives focused on menopause care, improved clinical guidance, and expanded reimbursement coverage are strengthening treatment accessibility. Healthcare providers are also placing greater emphasis on individualized menopause management, contributing to higher HRT prescription rates. Furthermore, the growing population of women aged 45 years and above creates a substantial patient base for hormone therapies. Continuous product innovation and increasing public discussion surrounding menopause are expected to further support market expansion across Australia in the coming years.

Australia Oral Hormone Replacement Therapy Market

The Australia Oral Hormone Replacement Therapy market remains an important segment within the broader HRT industry, supported by the long-standing use of oral estrogen and combined estrogen-progestogen therapies. Oral formulations continue to be widely prescribed due to their convenience, established clinical evidence, and familiarity among healthcare professionals. These therapies are commonly utilized for managing menopausal symptoms including hot flushes, night sweats, and hormonal imbalances. Although transdermal therapies are gaining popularity, oral HRT products continue to maintain strong demand, particularly among patients preferring traditional treatment approaches. Increasing awareness regarding menopause care, improved healthcare access, and favorable reimbursement policies are contributing to market growth. Continued availability of established oral brands is expected to support sustained adoption during the forecast period.

Australia Hospital Pharmacies Hormone Replacement Therapy Market

Hospital pharmacies represent an important distribution channel within the Australia Hormone Replacement Therapy market. These pharmacies play a critical role in dispensing hormone therapies prescribed by gynecologists, endocrinologists, and specialist menopause clinics. Hospital pharmacy channels are particularly important for newly diagnosed patients requiring clinical supervision, treatment initiation, and ongoing monitoring. The segment benefits from Australia's well-developed healthcare infrastructure and increasing patient referrals to specialist women's health services. Rising awareness of menopause management and growing demand for personalized treatment plans are supporting prescription volumes through hospital settings. Furthermore, the availability of a broad range of hormone formulations, including oral, transdermal, and vaginal products, enhances treatment accessibility. The expansion of specialist menopause services is expected to drive continued growth in hospital pharmacy-based HRT distribution.

Australia Hormone Replacement Therapy Market Segments:

Therapy Type

• Estrogen Hormone Replacement Therapy
• Human Growth Hormone Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Hormone Replacement Therapy
• Progestogen Hormone Replacement Therapy

Disease Type

• Menopause
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency
• Others

Route of Administration

• Oral
• Parental
• Others

Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

States

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Australian Capital Territory
• Tasmania
• Northern Territory

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Bayer AG
• Eli Lilly & Company
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Abbvie Inc. (Allergan plc)
• Teva Pharmaceutical Industries Ltd
• Dr. Reddy’s Laboratories Ltd

Report Details: